X4 Pharmaceuticals (XFOR) Common Equity (2017 - 2025)

X4 Pharmaceuticals' Common Equity history runs 9 years deep, the most recent figure standing at $186.3 million for Q4 2025.

• Quarterly Common Equity rose 741.08% year-over-year to $186.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $186.3 million (up 741.08% YoY) and the FY2025 annual result came in at $186.3 million, up 741.08% from the prior year.
• Common Equity was $186.3 million for Q4 2025 at X4 Pharmaceuticals, up from $61.6 million in the prior quarter.
• Across five years, Common Equity topped out at $186.3 million in Q4 2025 and bottomed at $1.0 million in Q1 2024.
• A 5-year average of $61.6 million and a median of $61.7 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity plunged 98.0% — and 2025, when it soared 2114.67%.
• X4 Pharmaceuticals' Common Equity stood at $64.4 million in 2021, then increased by 14.96% to $74.1 million in 2022, then sank by 30.99% to $51.1 million in 2023, then slumped by 56.65% to $22.1 million in 2024, then soared by 741.08% to $186.3 million in 2025.
• Business Quant data shows XFOR's Common Equity at $186.3 million in Q4 2025, $61.6 million in Q3 2025, and $4.0 million in Q2 2025.